Allergy Therapeutics - Articles and news items

Aloxi needle

First patient recruited in Pollinex Quattro Birch dose ranging study in Germany and Austria

Industry news / 1 September 2015 / Nick Jackson

As a precursor to the Phase III trial, this Phase IIb study will select the optimum dose, and is being conducted in Germany under the Therapy Allergens Ordinance (Therapieallergene-Verordnung)…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+